Pliant Therapeutics(PLRX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring bexotegrast's ef ect on total lung collagen and FVC in IPF patients expected in the coming weeks Regulatory clearance received for muscular dystrophy program PLN-101325, allowing conduct of a first-in-human Phase 1 cli ...